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a  b  s  t  r  a  c  t
Brazil  introduced  the  10-valent  pneumococcal  non-typeable  Haemophilus  inﬂuenzae  protein  D  conjugate
vaccine  (PHiD-CV,  SynﬂorixTM, GSK  Vaccines)  in the routine  childhood  immunization  program  in  2010
with  a 3  +  1  schedule  (with  catch-up  for children  <2  years-old).  This  review  represents  the  ﬁrst  anal-
ysis  of the  overall  impact  of  a second-generation  pneumococcal  conjugate  vaccine  on  nasopharyngeal
carriage  and all  the major  pneumococcal  disease  manifestations  in  a  single,  pneumococcal  conjugate
vaccine-naïve,  developing  country.  A total of 15  published  articles  and  13  congress  abstracts  were
included  in  the  analysis.  In children  <5  years-old,  studies  showed  a positive  impact  of  PHiD-CV  on the
incidence  of  vaccine-type  and  any-type  invasive  pneumococcal  disease  (including  decreases  in pneumo-
coccal  meningitis  morbidity  and  mortality),  on  pneumonia  incidence  and  mortality,  and  on  otitis  media.
Nasopharyngeal  carriage  of  vaccine-type  and  any-type  pneumococci  decreased  after  the primary  doses,cute otitis media
asopharyngeal carriage
with no early  signs  of replacement  with  other  pathogens.  Finally,  herd  protection  against  vaccine-type
invasive  pneumococcal  disease  and  pneumonia  in  unvaccinated  subjects  was  shown  in some  studies  for
some age groups.  In conclusion,  pneumococcal  disease  decreased  after  the  introduction  of PHiD-CV  into
the  Brazilian  national  immunization  program.  Further  follow-up  is needed  to evaluate  the  long-term
overall  impact  of  PHiD-CV  in  the  Brazilian  population.
e  Bio©  2016  GlaxoSmithKlin
. Introduction
The diseases caused by Streptococcus pneumoniae are a lead-
ng cause of morbidity and mortality in children <5 years-old
orldwide, especially in developing countries [1–4]. Pneumococ-
al diseases range from life-threatening invasive pneumococcal
iseases (IPD) such as meningitis, bacteremia, and bacteremic
neumonia, to the less serious but more frequent non-invasive
neumonia and acute otitis media (AOM) [1].
Abbreviations: AOM, acute otitis media; CI, conﬁdence interval; CVE, Centro
e Vigilância Epidemiológica; IAL, Instituto Adolfo Lutz; IPD, invasive pneumo-
occal disease; NS, statistically non-signiﬁcant; NTHi, non-typeable Haemophilus
nﬂuenzae;  NVT, non-vaccine type; PCV, pneumococcal conjugate vaccine; PHiD-CV,
neumococcal Haemophilus inﬂuenzae protein D conjugate vaccine; PM, pneumo-
occal meningitis; RCTs, randomized controlled trials; SINAN, Notiﬁable Diseases
nformation System; VE, vaccine effectiveness; VT, vaccine-type.
 Trademarks: Synﬂorix is a trademark of the GSK group of companies. Preve-
ar/Prevnar is a trademark of Pﬁzer/Wyeth LLC.
∗ Corresponding author at: GSK Vaccines, Building WN23, Avenue Fleming 20,
-1300 Wavre, Belgium. Tel.: +32 10859417.
E-mail address: marta.x.moreira@gsk.com (M.  Moreira).
ttp://dx.doi.org/10.1016/j.vaccine.2016.04.006
264-410X/© 2016 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an 
y/4.0/)logicals  SA. Published  by Elsevier  Ltd. This  is  an open access  article  under
the CC  BY license.  (http://creativecommons.org/licenses/by/4.0/)
Brazil is a large, upper middle-income country composed of ﬁve
regions with different climatic, demographic, and socioeconomic
characteristics. It has a mixed ethnic population of approximately
200 million with approximately 3 million births per year [5,6].
Brazil was the ﬁrst country in Latin America to introduce the 10-
valent pneumococcal non-typeable Haemophilus inﬂuenzae (NTHi)
protein D conjugate vaccine (PHiD-CV; SynﬂorixTM, GSK Vaccines)
into its routine national immunization program for all children [7].
PHiD-CV contains ten capsular polysaccharides from serotypes
1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, eight of them being
conjugated to the cell-surface protein D from NTHi, serotype 18C
conjugated to tetanus toxoid, and serotype 19F conjugated to diph-
theria toxoid. Implemented between March and September 2010,
the recommended vaccination schedule includes three primary
doses at 2, 4, and 6 months of age followed by a booster dose at
12–15 months of age (3 + 1 schedule) [7]. Catch-up schedules were
also set up by the Ministry of Health for older children: two  pri-
mary doses and a booster at 12–15 months were recommended for
infants 7–11 months-old, and one dose for children 12–23 months-
old. For high-risk children, the vaccine was recommended up to 5
years of age. In 2016, reduction to a 2 + 1 schedule (2 and 4 months
of age, and booster at 12 months of age) was  put in place [8].
open access article under the CC BY license. (http://creativecommons.org/licenses/
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Brazil has a national surveillance system of meningitis through
he Notiﬁable Diseases Information System (SINAN for Sistema de
nformac¸ ão de Agravos de Notiﬁcac¸ ão)  and the national reference
aboratory for meningitis and pneumococcal infections (IAL for
nstituto Adolfo Lutz, São Paulo). The municipalities or states also
ave the possibility to register morbidity and mortality data for
ther non-mandatory pneumococcal diseases via the uniﬁed health
ystem. Thus, 5 years after the introduction of PHiD-CV, Brazil
ffers an opportunity to measure the impact of the vaccine on
neumococcal disease in a large pediatric population in a coun-
ry with high vaccine coverage and available surveillance systems
9,10].
1032 references
identified  through 
PubMed, Embase, 
SciELO, or  hand search
847 re ference s ex cluded  
from title
60 potentially relevant 
references screened for 
eligibility
185 potentially relevant 
references screened 
from abstract
125 re ference s excluded  
from abstract
45 references  excluded 
from full text
15 references  included 
in the review  
ig. 1. Flow chart of the articles and congress abstracts evaluated for inclusion in the rev
neumoniae,  pneumococcal diseases, or topic-related diseases), not in Brazil (studies per
eference type (case reports, reviews, editorials, or comments), study type (animal studies
studies conducted among populations with chronic diseases not representative of the gen
public health programs or recommendations, cost-effectiveness or health economics stu
studies  of virus etiology only), study period (studies conducted only before or after PH
ext  not available), duplicated (studies presented several times), and published (congress
nalysis).4 (2016) 2766–2778 2767
In this review, we examined the impact of PHiD-CV introduction
in the Brazilian national immunization program on IPD, pneumo-
nia, AOM, and nasopharyngeal carriage. We also examined herd
protection in unvaccinated age groups.
2. Methods
2.1. Search strategy and selection criteriaWe conducted a search of the literature in three differ-
ent online databases (PubMed, Embase, and SciELO) to identify
reports of studies investigating the possible effects of PHiD-CV
715 potential ly relevant 
abstracts from  selected 
congresses
13 abstracts included in 
the review 
675 abstracts  excluded 
40 potentiall y relevant 
abstracts screened for 
eligibility
27 abstracts excluded
Reference  type
Not PHiD-CV
Study type
Popul atio n
Public he alth
Viral  etiolog y
Not in  Brazil
Irrelevant
Published
Not availa ble
Study peri od
Treatments
Dupli cated
iew. Reasons for exclusions were: irrelevance (studies not analyzing Streptococcus
formed in other countries), not PHiD-CV (studies of vaccines other than PHiD-CV),
, in vitro studies, models, or vaccine immunogenicity or safety studies), population
eral population or, for topic-related diseases, in too-old populations), public health
dies), treatments (studies evaluating treatments such as antibiotics), viral etiology
iD-CV introduction or whose analysis period was unspeciﬁed), not available (full
 abstracts whose results were also described in a published article included in the
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n pneumococcal disease in Brazil [11–13]. Reports had to be in
nglish, Portuguese, or Spanish and published between January
011 and April 2015. Search terms included various combinations
f terms as described in Supplementary Appendix A. Additional
earches were done in PubMed to identify articles published
etween April and November 2015, and between December 2015
nd February 2016.
We  included all randomized controlled trials (RCTs), non-
andomized studies, and observational studies assessing the effects
f PHiD-CV introduction in Brazil on IPD, pneumonia, AOM,
asopharyngeal carriage, or herd protection in all age groups. The
ear of PHiD-CV introduction, 2010, was considered as a transition
eriod. We  also included studies evaluating vaccination coverage
ate after PHiD-CV introduction. In addition, we included articles
hat evaluated the prevalence or incidence of other diseases related
o the same topics (bronchitis, bronchiolitis, asthma, reactive air-
ay disease, sinusitis, pharyngitis, tonsillitis, and conjunctivitis)
efore and after 2010 in children ≤5 years-old.
We excluded reports of animal or in vitro studies; immuno-
enicity or safety studies; cost-effectiveness studies; public health
ecommendations; case reports; editorials; studies of viral etiology
nly; studies conducted among populations with chronic diseases
ot representative of the general population; or studies whose
nalysis period was unspeciﬁed. Reviews were excluded but their
ibliographies were examined for additional potentially relevant
rticles.
First, two reviewers independently screened the titles of all
etrieved articles. Then, three different reviewers independently
ig. 2. Brazilian regions and cities with data included in this analysis. (A) Invasive pneum
ears-old and herd protection in unvaccinated age groups. (C) Pneumonia and acute otitis
idades.ibge.gov.br/xtras/home.php) and maps were obtained from the Presentation Maga
titis  media; CAP, community-acquired pneumonia; IPD, invasive pneumococcal disease4 (2016) 2766–2778
screened the abstracts of the selected articles for relevance. In a
third step, the full texts of the selected reports were assessed for
eligibility using pre-deﬁned inclusion and exclusion criteria. At all
stages, reviewers reached a consensus for inclusion or exclusion of
the articles.
We  also searched the abstracts of relevant scientiﬁc con-
gresses held between January 2011 and May  2015 (Supplementary
Appendix A) and screened them with the same inclusion and exclu-
sion criteria used for the articles. Abstracts were not included if
the results were also described in a published article included in
the analysis. When several abstracts were presented for the same
study, the most recent or most complete data were used.
Finally, we  searched for additional epidemiological data on
the websites of SINAN, Centro de Vigilância Epidemiológica (CVE)
“Alexandre Vranjac” in São Paulo, and the Brazilian government
open-access public health database system DATASUS [14–16].
3. Results
3.1. Results of the literature search
The literature search identiﬁed 1032 potentially relevant arti-
cles, of which 60 were retrieved for full text analysis (Fig. 1).
Of them, 15 met  the inclusion criteria and were included in the
analysis. Two  studies were case–control studies [17,18], one was
an indirect cohort study [19], and ten were time-series or cross-
sectional analyses [20–29]. Two articles described only coverage
ococcal disease in children <5 years-old. (B) Nasopharyngeal carriage in children <5
 media in children <5 years-old. Population data was based on 2010 census (http://
zine website (http://www.presentationmagazine.com/editable-maps). AOM,  acute
; NPC, nasopharyngeal carriage; PM,  pneumococcal meningitis.
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ates [9,30]. In addition, 13 out of the 715 screened congress
bstracts were included.
.2. Vaccination coverage
The Brazilian Ministry of Health provides information on vac-
ination coverage based on the number of administered doses
egistered in an administrative database (DATASUS). At the national
evel, the coverage for the three primary doses of PHiD-CV was
4% in 2010, 82% in 2011, 88% in 2012, 94% in 2013, and 93%
n 2014 [31]. Preliminary data for 2015 suggested that coverage
or the three primary doses was similarly high. These data were
eferred to in several studies [20,28,30,32,33]. However, coverage
ates differed by city. Soon after the introduction of PHiD-CV, cov-
rage rates for the three primary doses in Belo Horizonte, Curitiba,
nd Recife reached approximately 100%, whereas coverage was
5% in Porto Alegre and 75% in São Paulo in July 2011 [22]. In
oiania, two studies showed similar lower coverage rates [9,29].
 household survey performed from December 2010 to February
011 indicated coverage of 53.4% for the three primary doses [9].
n active population-based surveillance study indicated that the
verall coverage rate for a complete 3-dose primary series before
2 months of age was 58%, with a lower rate for 24–35 months-old
50.3%) than for 2–23 months-old (61%) [29]. No information was
ublished about coverage for the booster dose administered in the
econd year of life.
.3. Invasive pneumococcal disease
.3.1. In the vaccinated cohort
Seven articles and six abstracts analyzed the effect of PHiD-CV
n IPD or pneumococcal meningitis only in young children (Fig. 2A,
able 1). A matched case–control study published in 2014 was  con-
ucted in ten Brazilian states using laboratory- and hospital-based
urveillance to identify IPD cases among children eligible to have
eceived at least one dose of PHiD-CV [18]. The analysis included
16 IPD cases and 1219 age- and neighborhood-matched controls
rom March 2010 through December 2012. The adjusted vaccine
ffectiveness (VE) against vaccine-type (VT) IPD was 83.8% (95%
onﬁdence interval [CI], 65.9–92.3%) for an age-appropriate vaccine
chedule and 68.0% (95% CI, 17.6–87.6%) for one catch-up dose in
hildren aged 12–23 months. In addition, VE against IPD was 87.7%
95% CI, 60.8–96.1%) for serotype 14 and 82.8% (95% CI, 23.8–96.1%)
or serotype 6B (the two most common vaccine serotypes) and
2.2% (95% CI, 10.7–96.4%) for the vaccine-related serotype 19A
18]. Using these 316 cases, the same group performed an indi-
ect cohort analysis, in which the vaccination status of patients
ith VT IPD was compared with that of non-vaccine-type (NVT)
PD [19]. The results of this analysis were consistent with those
f the case–control study, with adjusted effectiveness of ≥1 dose
f 72.8% (95% CI, 44.1–86.7%) against VT IPD and of 61.3% (95% CI,
4.5–82.5%) against vaccine-related IPD.
Several observational studies have shown a decrease in IPD inci-
ence after PHiD-CV introduction in Brazil. A time-series analysis
onducted in a university hospital in São Paulo between 2006 and
012 showed an 80% decrease in the overall IPD incidence rate per
000 admissions among <2 years-old (from 20.3 to 3.97) and a
7% decrease in VT IPD incidence rate (from 16.47 to 0.44) after
HiD-CV introduction [21]. A laboratory-based national surveil-
ance in reference hospitals showed that, 2 years after PHID-CV
ntroduction, VT IPD cases numbers decreased by 85% in vaccinated
hildren [33]. In a sentinel hospital in São Paulo for 2009–2012,
he annual number of overall IPD and VT IPD cases in <2 years-old
ecreased by 77% and 89%, respectively, in the post-introduction
eriod [32]. No increase in NVT IPD cases was observed. A reduc-
ion in penicillin resistance rates was also observed in this study.4 (2016) 2766–2778 2769
Finally, an interrupted time-series analysis using conﬁrmed pneu-
mococcal meningitis cases notiﬁed to SINAN and all IPD cases from
the national reference laboratory (adjusted for seasonality and sec-
ular trends) suggested that PHiD-CV reduced IPD rates by 44.2%
(95% CI, 15.8–72.5%) between 2008–2009 and 2011–2013 [28]. In
contrast to all other studies on IPD, in Porto Alegre, a study ana-
lyzing 325 pneumococcal strains isolated from IPD patients of all
ages between 2007 and 2012 showed that, in ≤2 years-old, the fre-
quency of VT isolates before and after introduction did not differ
(58.8% vs 58.3%; n = 29 isolates) [23].
Three studies (reported as two  articles and two abstracts) ana-
lyzed cases of pneumococcal meningitis reported to SINAN and
produced similar results [24,25,34,35]. A cross-sectional retrospec-
tive study comparing the incidence and mortality of pneumococcal
meningitis in 1998–2009 vs 2010–2011 in Paraná state showed sig-
niﬁcant reductions in incidence rate/100,000 population (60%, from
6.21 to 2.49) and mortality rate (76%, from 1.92 to 0.47) in <2 years-
old [24]. An ecological study that reviewed national data showed a
50% reduction in the incidence rate and 69% in the mortality rate
from pneumococcal meningitis in ≤2 years-old between 2007 and
2012 [25]. Preliminary SINAN data also showed that pneumococcal
meningitis rates per 100,000 persons in <2 years-old decreased by
50% from an average of 10.2 in the pre-vaccination baseline period
(2001–2009) to 5.1 in 2011 [34]. A decrease of 44% was  seen when
using years 2007–2009 as the baseline [35].
In addition, in a hospital-based surveillance in the city of
Salvador, the incidence of pneumococcal meningitis tended to
decrease in <2 years-old between January 2008–May 2010 and June
2010–December 2012 (p < 0.058) [36]. The overall case-fatality rate
decreased from 24% to 17.6%.
3.3.2. In the unvaccinated cohort
To evaluate the herd protection induced by PHiD-CV, its impact
on VT IPD has also been assessed in unvaccinated children >2 years-
old and adults. Initial results from a retrospective surveillance of
IPD in a sentinel hospital in São Paulo showed that, in <16 years-old,
the prevalence of VTs decreased after vaccination (62% vs 35.5%)
and the prevalence of NVTs did not increase [37]. Changes in over-
all disease rate, which is a combination of VT and NVT changes,
were also assessed. Overall IPD cases/1000 admissions decreased
from 4.7 in 2007–2009 to 3.7 in 2010 (transition period) and to 2.2
in 2011–2014 [37,38]. The distribution of clinical diagnoses and
IPD mortality did not change over time in this study [38]. Using
national surveillance data, a signiﬁcant herd effect for VT IPD was
observed two  years after PHiD-CV introduction in all age-groups
except in adults ≥65 years-old [33]. Finally, in a prospective lab-
oratory surveillance, the incidence of overall IPD cases/100,000
inhabitants in Salvador declined by 20% in ≥50 years-old (from 0.36
to 0.29), and by 23% in ≥60 years-old (from 0.26 to 0.20) between
2008–2009 and 2010–2013 [39].
Two  retrospective hospital-based studies were not able to detect
a signiﬁcant effect on the overall IPD incidence in unvaccinated
populations two years after PHiD-CV introduction (Fig. 2B, Table 2)
[21,23]. First, in a time-series analysis conducted in a university
hospital in São Paulo between 2006 and 2012, no signiﬁcant effect
of PHiD-CV introduction was seen on overall IPD or VT IPD incidence
in >15 years-old but the incidence of overall IPD and VT IPD tended
to decrease (25% and 65%, respectively) in 2–14 years-old [21]. Sec-
ond, in the study analyzing 325 strains isolated from IPD patients of
all ages in Porto Alegre, no signiﬁcant difference was  seen between
the proportion of VT strains isolated before (51.5% in 2007–2010)
and after PHiD-CV introduction (48.1% in 2011–2012) [23]. Also,
no net effect was observed in unvaccinated 2–17 years-old and
an increase was  observed in adults ≥18 years in an interrupted
time-series analysis using all IPD cases from the national reference
laboratory and conﬁrmed pneumococcal meningitis cases notiﬁed
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Table 1
Impact of PHiD-CV on invasive pneumococcal disease in Brazil in children <5years of age.
Reference Region/city Study type Study period Sample size Age group Outcome Effectiveness or percent
decrease (95% CI)
Incidence or
percentage of cases
Pre-
introduction
Post-
introduction
Domingues et al.
[18]
10 states Matched case–
control study
March 2010–
December 2012
316 cases + 1219
controls (4 age-
and neighborhood-
matched per
case)
<5 years VT IPD 83.8% (65.9–92.3%)a – –
81.9% (64.4–90.8%)b
ST6B IPD 82.8% (23.8–96.1%)a
ST14 IPD 87.7% (60.8–96.1%)a
Vaccine-related IPD 77.9% (41.0–91.7%)a
ST19A IPD 82.2% (10.7–96.4%)a
NVT IPD 37.5% (−65.4 to 76.4%)a
Verani et al. [19] 10 states Indirect cohort
study (Broome
method)
March 2010–
December 2012
316 cases <5 years VT IPD 72.8% (44.1–86.7%)b – –
73.9% (41.9–88.3%)a
ST6B IPD 69.7% (16.5–89.0%)b
65.0% (−8.5 to 88.7%)a
ST14 IPD 75.4% (43.2–89.4%)b
75.8% (37.4–90.7%)a
Vaccine-related IPD 61.3% (14.5 to −82.5%)b
64.8% (15.3–85.4%)a
ST19A IPD 71.3% (16.6 to −90.1%)b
63.4% (−16.8 to 88.6%)a
dos Santos et al.
[21]
City of São Paulo Time-series
analysis
(University
hospital)
Pre: January
2006–June 2010
Post: July
2010–September
2012
259 patients (89 in
<2 years)
<2 years Overall IPD
VT IPD
NVT IPD
80.4%c; p = 0.0012
97.3%c; p = 0.0002
18.2%c; NS
20.30/103
16.47/103
3.80/103
3.97/103
0.44/103
3.11/103
Caierão et al. [23] City of Porto
Alegre
Retrospective
study
Pre: 2007–2010
Post: 2011–2012
325 samples (29
in  <2 years)
<2 years VT IPD No decreasec 58.8% 58.3%
<5  years No decreasec 52.4% 58%
Berezin  et al. [59]
(abstract)
Cities of São Paulo
and Uberlandia
Retrospective
study (2 university
hospitals)
Pre: 2005–2009
Post: 2010
135 patients <5 years VT IPD – 71.3% 65.0%
Andrade et al. [28] Nationwide Interrupted
time-series
analysis
(IPD data from
SINAN and PM
cases from IAL)
Pre: 2008–2009
Post: 2011–2013
9827 cases overall <2 years Overall IPD 2–23 months: 44.2%
(15.8–72.5%)c; p < 0.0001
– –
2–11 months: 34.7%
(10.4–58.9)c;  p = 0.002
12–23 months: 61.1%
(39.6–82.7)c; p < 0.0001
Brandileone et al.
[33] (abstract)
Nationwide Passive
surveillance
Pre: 2008–2009
Post: 2011–2012
2399 isolates (174
in  <2 years)
<2 years VT IPD (annual median
of  isolate numbers)
85%c; p < 0.005 – –
Safadi  et al. [32]
(abstract)
City of São Paulo Hospital-based
surveillance
2004–2012 94 cases <2 years VT IPD 89%c – –
Overall IPD 77%c
NVT IPD No increasec
Hirose et al. [24] State of Parana Observational,
cross-sectional
study with
retrospective data
collection (SINAN)
Pre: 1998–2009
Post: 2010–2011
1339 cases overall <2 years PM
PM mortality
59.9%c; p < 0.01
75.5%c; p < 0.01
6.21/105
1.92/105
2.49/105
0.47/105
Grando et al. [25] Nationwide Descriptive study
and ecological
analysis of cases
reported to SINAN
Pre: 2007–2009
Post: 2011–2012
1311 cases ≤2 years PM
PM mortality
50.3%c
69.2%c
3.70/105
1.30/105
1.84/105
0.40/105
M. Moreira et al. / Vaccine 3
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to SINAN (adjusted for seasonality and secular trends) between
2008–2009 and 2011–2013 [28].
Preliminary results from a hospital-based surveillance study in
the city of Salvador suggested that the incidence of pneumococ-
cal meningitis per 100,000 persons decreased from 0.71 (January
2008–May 2010) to 0.46 (June 2010–December 2012) in all-age
patients [36]. Similarly, the incidence of VT pneumococcal meningi-
tis decreased from 0.31 to 0.15 cases/100,000 persons [36]. Another
hospital-based surveillance in Salvador also showed that the annual
incidence of pneumococcal meningitis cases/100,000 population
decreased from 1.65 in 1996 to 0.2 in 2012, and the incidence
rate of penicillin nonsusceptible pneumococci decreased 82% over
this 17-year period, suggesting an important effect in unvaccinated
groups although this study did not compare incidence in <2 and ≥2
years-old [27].
3.4. Pneumonia
3.4.1. In the vaccinated cohort
Eight reports, including four abstracts, evaluated the impact of
PHiD-CV introduction on pneumonia (Fig. 2C, Table 3). A retro-
spective analysis of the governmental open-access public health
DATASUS database reported that hospitalization rates for pneu-
monia in <4 years-old (i.e., including vaccinated and unvaccinated
children) decreased by 12.7% between the pre-PHiD-CV period
(2002–2009) and the 2 years following PHiD-CV introduction [20].
Notably, the decreasing incidence of pneumonia admissions was
not associated with changes in incidence of non-respiratory admis-
sions (p = 0.39) [20].
Another study using secondary data from the National Hos-
pitalization Information System analyzed hospitalizations for
all-cause pneumonia (after subtracting hospitalization rates for
non-respiratory causes) among 2–24 months-old between January
2005 and August 2011 in ﬁve Brazilian cities [22]. Adjusted hospi-
talization rates for pneumonia decreased signiﬁcantly between the
pre-PHiD-CV period and one year after PHiD-CV introduction in
Belo Horizonte (28.7%), Curitiba (23.3%), and Recife (27.4%), where
PHiD-CV coverage was approximately 100% in 2011, but not in
São Paulo and in Porto Alegre, two  cities with lower coverage
(∼80%) [22]. A study evaluating the impact of PHiD-CV introduc-
tion in the city of Guaranésia using hospitalization records and
outpatient visits for respiratory diseases showed that the preva-
lence of community-acquired pneumonia cases in <2 years-old
decreased by 40% (p < 0.05) after vaccine introduction (2009–2010
vs 2011–2012) [26].
Preliminary results of a population-based study conducted in
Goiania between December 2010 and March 2011 using a random
sample of 1291 children 7–18 months-old suggest that PHiD-CV
VE was 40% (95% CI, 1.4–63%) against community-acquired pneu-
monia in completely vaccinated children [40]. Another study in
Goiania using primary data from an active population-based pneu-
monia surveillance showed that, from May  2007–2009 to October
2011–2013, all-cause pneumonia admission rates decreased by
13.1% in 2–23 months-old and by 7.4% in 24–35 months-old
(p = 0.06) [29]. Similarly, in an interrupted time-series analysis of
data from the Brazilian Hospitalization System from 2005 to 2013
(excluding 2010 and the 2009 H1N1 inﬂuenza pandemic months),
pneumonia hospitalization rates in 2–23 months-old decreased by
16.6% after PHiD-CV introduction [41].
Initial results of an interrupted time-series analysis (2005–2012
excluding the 2009 H1N1 inﬂuenza pandemic months), using data
from the Brazilian Mortality Information System database from all
26 state capitals and the Federal District, showed an overall reduc-
tion of 16.9% in pneumonia mortality in 2–23 months-old after
PHiD-CV introduction compared to mortality due to other respi-
ratory causes (p = 0.001) [42].
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Table 2
Impact of PHiD-CV on nasopharyngeal carriage and herd protection in Brazil.
Reference Region/city Study type Study period Sample size Age group Outcome Effectiveness or
percent decrease (95%
CI)
Incidence or
percentage of cases
Pre-
introduction
Post-
introduction
Andrade et al. [17] City of Goiania Cross-sectional
population-based
household survey
December
2010–February
2011
1287 children 7–18 months VT carriage (3
doses)
44.0% (14.0–63.5%)a;
p = 0.008
– –
VT carriage (2
doses)
35.9% (4.2–57.1%)a;
p = 0.03
1 catch-up dose No effecta; p = 0.905
Andrade et al. [40]
(abstract)
City of Goiania Population-based
study
December
2010–March 2011
1291 samples 7–18 months All-type carriage
(complete
vaccination)
36% (12–53%)a – –
All-type carriage
(incomplete
vaccination)
26% (0–50%)a
dos Santos et al.
[21]
City of São Paulo Time-series
analysis
(University
hospital)
Pre: January
2006–June 2010
Post: July
2010–September
2012
259 patients (170
in ≥2 years)
≥2 years VT IPD 2–14 years: 65.4%b; NS
≥15 years: −32.9%c; NS
2.81/103
0.85/103
0.97/103
1.13/103
Overall IPD 2–14 years: 24.8%b; NS 3.35/103 2.52/103
≥15 years: −83.7%c; NS 1.72/103 3.16/103
Caierão et al. [23] City of Porto Alegre Retrospective
study
Pre: 2007–2010
Post: 2011–2012
325 isolates overall All ages (mean,
45.2 years)
VT IPD No decreaseb;
p = 0.5411
51.5% 48.1%
Brandileone et al.
[33] (abstract)
Nationwide Passive
surveillance
Pre: 2008–2009
Post: 2011–2012
2399 isolates
overall
≥2 years VT IPD (annual
median of isolate
numbers)
2–4 years: 50%b;
p = 0.048
– –
5–49 years: 40%b;
p  = 0.005
50–64 years: 47%b;
p  = 0.021
≥65 years: NSb;
p = 0.662
Andrade et al. [28] Nationwide Interrupted
time-series
analysis (IPD data
from SINAN and
PM cased from IAL)
Pre: 2008–2009
Post: 2011–2013
9827 cases overall ≥2 years Overall IPD 2–4 years: −14.7%
(−115.1 to 85.7)c;
p  = 0.347
– –
5–9 years: 4.7%
(−56.7 to 66.0)b;
p = 0.660
10–17 years: −6.2%
(−85.2 to 72.9)c;
p = 0.465
18–39 years: −18.9%
(−36.7 to −1.1)c;
p = 0.018
40–64 years: −52.5%
(−80.3 to −24.8)c;
p < 0.0001
≥65 years: −79.3%
(−96.5 to −62.1)c;
p < 0.0001
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Azevedo et al. [39] (abstract) City of Salvador Prospective
laboratory
surveillance
Pre: 2008–2009
Post: 2010–2013
– ≥50 years Overall IPD ≥50 years: 20%b
≥60 years: 23%b
– –
Jarovsky et al.
[37,38] (abstracts)
São Paulo Hospital-based
retrospective
surveillance
Pre: 2007–2009
Transition: 2010
Post: 2011–2014
94 episodes <16 years Overall IPD – 4.7/103
(transition:
3.7/103)
2.2/103;
(p = 0.001)
VT  IPD 62% 35.5%
(p = 0.001)
IPD mortality 0.04% 0.07%
Lobo  et al. [36]
(abstract)
City of Salvador Hospital-based
surveillance
Pre: January
2008–May 2010
Post: June
2010–December
2012
104 cases All ages PM – 0.71/105 0.46/105
(p < 0.03)
VT  PM 0.31/105 0.15/105
(p < 0.03)
PM case fatality
rate
24% 17.6%
dos  Santos et al. [27] City of Salvador Active
hospital-based
surveillance
Pre: 1996
Post: 2012
All ages PM – 1.65/105 0.2/105
Andrade et al. [41]
(abstract)
Nationwide Interrupted
time-series
analysis (Brazilian
hospitalization
data)
Pre: 2005–2009
Post: 2011–2013
– ≥2 years Pneumonia
hospitalizations
2–4 years: 14.4%b;
p = 0.024
– –
5–9 years: 17.4%b;
p = 0.001
10–17 years: 14.1%b;
p  < 0.0001
18–39 years: 15.2%b;
p < 0.0001
40–64 years: 4.8%b;
p = 0.141b
≥65 years: −9.9%c;
p = 0.004
CI, conﬁdence interval; IAL, Instituto Adolfo Lutz; IPD, invasive pneumococcal disease; PM,  pneumococcal meningitis; NS, statistically non-signiﬁcant; SINAN, Notiﬁable Diseases Information System; VT, vaccine-type (serotypes
1,  4, 5, 6B, 7F, 9V, 18C, 19F, and 23F).
a Effectiveness.
b Percent decrease.
c A negative value indicates an increase.
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Table 3
Impact of PHiD-CV on pneumonia, acute otitis media, and sinusitis in Brazil.
Reference Region/city Study type Study period Sample size Age group Outcome Percent decrease
(95% CI)
Incidence
Pre-introduction Post-introduction
Scotta et al. [20] Nationwide Retrospective
analysis (data from
DATASUS)
Pre: 2002–2009
Post: 2011–2012
15,147,996 admissions,
including 3,514,750 for
pneumonia (23.2%)
<4 years Pneumonia
hospitalizations
12.7%; p < 0.001 2801/105 2447/105
Afonso et al. [22] 5 state capitals Interrupted
time-series
analysis
(individual-level
secondary data)
Pre: January
2005–February 2010
(except Porto Alegre:
May  2010)
Post: 4 months after
introduction–August
2011
197,975
hospitalizations,
including 59,636 for
pneumonia (30.1%)
<2 years Pneumonia
hospitalizations
(adjusted for
non-respiratory
causes
hospitalizations)
Belo Horizonte:
28.7%; p = 0.002
Recife: 27.4%;
p = 0.007
Curitiba: 23.3%;
p  = 0.011
Porto Alegre: 2.3%;
p = 0.845
São Paulo: 1.8%;
p = 0.827
– –
Abrão  et al. [26] City of Guaranésia Cross-sectional
study in primary
care and hospitals
Pre: 2009–2010
Post: 2011–2012
377 records <2 years CAP PR: 0.60
(0.46–0.78);
p < 0.05
– –
AOM PR: 0.77 (0.60–1.0);
p > 0.05
Sinusitis PR: 1.05
(0.65–1.70);
p > 0.05
Andrade et al. [41]
(abstract)
Nationwide Interrupted
time-series
analysis (Brazilian
hospitalization
data)
Pre: 2005–2009
Post: 2011–2013
– <2 years Pneumonia
hospitalizations
16.6%; p = 0.016 – –
Andrade et al. [40]
(abstract)
City of Goiania Population-based
study
December
2010–March 2011
1291 samples 7–18 months CAP (complete
vaccination)
40% (1.4–63%)
Sgambatti et al.
[29]
City of Goiania Active
population-based
surveillance
Pre: May
2007–April 2009
Post: November
2011–October
2013
8191 samples 2–23 months
24–35 months
All-cause
pneumonia
hospitalizations
2–23 months:
13.1% (12.9–13.4)
5728/105 4976/105
2–11 months:
12.6% (12.3–12.9)
6788/105 5935/105
12–23
months:14.2%
(13.7–14.6)
4802/105 4122/105
24–35 months:
7.4% (7.1–7.8)
2408/105 2229/105
Minamisava et al.
[42] (abstract)
26 state capitals and
Federal District
Interrupted
time-series
analysis (Brazilian
mortality data)
Pre: 2005–2009
Post: 2011–2012
– <2 years Pneumonia
mortality
16.9%; p = 0.001 – –
Sartori  et al. [43]
(abstract)
City of Goiania Time-series
analysis
(individual-level
secondary data)
Pre: January
2008–May 2010
456,153 outpatient
visits, including
6177 (1.4%) due to
all-cause otitis, and
241,379 (52.9%) to
other causes.
<2 years Outpatients visits
for all-cause AOM
44.5%
(43.2–45.7%);
p < 0.0001a
– –
Post:  June
2010–August 2013
1.58% (0.41–2.73%)
monthly; p = 0.009
AOM, acute otitis media; CAP, community-acquired pneumonia; CI, conﬁdence interval; PR, prevalence ratio.
a Personal communication.
cine 3
3
i
f
w
i
d
I
T
p
3
A
f
a
o
o
v
0
s
i
[
b
p
r
a
P
c
o
i
(
3
c
c
f
2
t
d
C
n
b
t
m
v
[
4
o
a
d
s
n
P
i
P
t
V
wM. Moreira et al. / Vac
.4.2. In the unvaccinated cohort
Preliminary results of a study using data from the Brazil-
an Hospitalization System from 2005–2013 (previously described
or the vaccinated cohort) showed that, 3 years after PHiD-CV
as introduced, hospitalizations for pneumonia were also lower
n unvaccinated children and adults <40 years-old (14.1–17.4%
ecreases), consistent with a herd effect (Fig. 2B, Table 2) [41].
n contrast, pneumonia rates increased by 9.9% in ≥65 years-old.
he authors estimated that, nationally, 224,542 hospitalizations for
neumonia were avoided since the introduction of PHiD-CV [41].
.5. Acute otitis media and sinusitis
One article evaluated the impact of PHiD-CV introduction on
OM and sinusitis (Fig. 2C, Table 3) [26]. This retrospective study
ound no decrease in the prevalence of all-cause AOM and sinusitis
fter vaccine introduction (2009–2010 vs 2011–2012) in <2 years-
ld in the city of Guaranésia. However, in a separate comparison
f vaccinated vs non-vaccinated individuals, they mentioned that
accination protected against AOM (prevalence ratio = 0.47, 95% CI,
.35–0.64; p < 0.05) [26].
Another study in Goiania, presented as an abstract, showed a
igniﬁcant reduction in outpatient visit rates due to all-cause otitis
n children 2–23 months-old, 3 years after PHiD-CV introduction
43]. All 2–23 months-old children with all-cause otitis diagnosis
etween January 2008 and August 2013 were identiﬁed, and out-
atient visits due to other causes were used as comparators. The
ate of all-cause otitis visits per 10,000 children decreased by an
verage of 1.58% each month (95% CI, 0.41–2.73%; p = 0.009) after
HiD-CV was introduced, whereas the rate of visits due to other
auses increased by 0.51% (95% CI, 0.06–0.95%; p = 0.026) [43]. The
verall decrease in all-cause otitis visit rate was 44.5% in the post-
ntroduction period, whereas childcare visits increased by 17.8%
personal communication).
.6. Nasopharyngeal carriage
One study evaluated the impact of PHiD-CV on pneumococ-
al nasopharyngeal carriage, necessary for herd protection. This
ross-sectional population-based household survey was conducted
or 7–18 months-old in Goiania from December 2010 to February
011 (Fig. 2B, Table 2) [17]. After adjustment for confounding fac-
ors, VT carriage rates were lower in children who  received two
oses (VE, 35.9%; 95% CI, 4.2–57.1%) or three doses (VE, 44.0%; 95%
I, 14.2–63.5%) than in non-vaccinated children. VT carriage was
ot signiﬁcantly lower in children who received one catch-up dose
etween 12 and 23 months of age [17]. A preliminary analysis of
his study also suggested that adjusted VE against overall pneu-
ococcal carriage was 36% (95% CI, 12–53%) for complete primary
accination and 26% (95% CI, 0–50%) for incomplete vaccination
40].
. Discussion
This review represents the ﬁrst analysis of the overall impact
f a second-generation pneumococcal conjugate vaccine (PCV) on
ll the major pneumococcal disease manifestations in a single
eveloping country. In children <5 years-old, despite an increased
urveillance as of the introduction of PCV in the national immu-
ization program, all studies but one showed a positive impact of
HiD-CV on the incidence of vaccine-type and any-type IPD, includ-
ng decreases in pneumococcal meningitis morbidity and mortality.
neumonia hospitalizations and mortality and outpatient visits due
o all-cause otitis media also decreased. Nasopharyngeal carriage of
T and any-type pneumococci decreased after the primary doses,
ith no early signs of replacement with other pathogens. Finally,4 (2016) 2766–2778 2775
herd protection against VT IPD and pneumonia in unvaccinated
subjects was shown in some studies for some age groups. These
ﬁndings support cost-effectiveness analysis suggesting that the
introduction of PHiD-CV in the national immunization program has
the potential to markedly reduce the overall health and economic
burden of pneumococcal disease in Brazil [44].
These results are aligned with those from two  double-blind RCTs
of PHiD-CV in Finland (FinIP; NCT00861380) and Latin America
(COMPAS; NCT00466947). Both studies showed that PHiD-CV is
highly effective in preventing pneumococcal diseases [45,46]. Sim-
ilar impact on VT IPD in unvaccinated populations was observed
in Brazil and in Finland (Fig. S1). With sustainable and consis-
tent surveillance allied with comprehensive coverage estimations,
we believe that Brazil may help provide further information on
the duration of protection in the PHiD-CV-vaccinated cohort and
the overall impact on IPD in a developing country, including
vaccine-related, NVT disease (replacement phenomena), and herd
protection.
Overall PHiD-CV coverage rapidly increased after it was
introduced; however, vaccination coverage was  only 54.6% (95% CI,
52.1–57.7%) in Goiania 6–8 months after its introduction [47]. The
national vaccination coverage register reports coverage of ∼94% for
the 3 primary doses in 2013 and 2014 but information about the
booster dose, which is important for the duration of protection, is
not found in the register nor in published references [48,49].
Although serotype 19A was not common in Latin America before
the introduction of PCVs, the case–control and the indirect cohort
studies in Brazil provides reassurance on the effectiveness of PHiD-
CV in prevention of IPD due to this serotype [18,19,50,51]. However,
the impact of PCVs on overall IPD should be monitored, because
it includes VT and vaccine-related-types but also accounts for the
emergence of NVT disease.
5. Limitations
A non-systematic review has several limitations such as sub-
jectivity on study selection and lack of analysis of study quality or
risk of bias. While we  recognize the varying robustness of research
methodology across the studies, we  did not systematically assess
their quality. For instance, some of the studies included were
limited by small sample size, unclear population denominators,
or risks of bias. Some studies only showed changes in VT IPD and
others only on overall IPD. This and the limited age groups exam-
ined within a given study can make it difﬁcult to get a complete
picture or to determine what might be speciﬁcally attributable
to vaccination. Also, the age ranges of populations analyzed were
not consistent between studies, which may  prevent direct compar-
isons.
Although the surveillance systems were usually based on pas-
sive surveillance in hospital settings rather than on more accurate
active surveillance, they have produced serotype distribution base-
line data that, together with the case control and time-series
population analysis, allowed for an initial evaluation of vaccine
impact. Use of secondary data such as hospitalization databases
may  bias the results, for instance due to misclassiﬁcation or changes
in coding practices [52]. A conservative approach using internal
controls (e.g., comparison with an unrelated disease rate) was used
in some studies to limit biases [17,22,28]. However, this approach
may  prevent comparisons between studies and may offset a net
impact on disease [28].
Pre-/post-introduction analyses should be interpreted with
caution because other changes may  occur simultaneously to the
introduction of the vaccine and skew the results. For instance, the
use of PCR for meningitis diagnosis and the shipment of isolates
to the central national laboratory both increased after PHiD-CV
introduction due to an ongoing case–control study involving
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ctive solicitation of blood culture isolates [18]. It may  have offset
HiD-CV impact on IPD, as potentially observed in some of the
tudies described [22,23]. Analysis of the CVE data showed a
eneral increase in S. pneumoniae, H. inﬂuenzae,  and Neisseria
eningitidis cases in children <2 years-old in the São Paulo state in
010 (Table S1), suggesting a global improvement in case reporting
nd detection methods. A general increase has not been observed
n the SINAN national register for pneumococcal meningitis in
1 years-old, although the numbers of meningococcemia and
neumococcal meningitis slightly increased in all-age population
n 2010. Population-based time-series analyses are more robust
ecause they can adjust for pre-vaccination or secular trends [52].
n addition, we think that the reproducibility of the directionality
nd magnitude of some key results seen here (i.e., decrease in VT
nd overall IPD in children) provide conﬁdence that these changes
re linked to vaccine implementation.
Herd protection against VT IPD and pneumonia in unvaccinated
ge groups was observed but a detailed analysis of the possible
erd effect will require a continuous follow-up. Indeed, all stud-
es but one analyzed data up to 2012 or 2013, which is only 2–3
ears after the introduction of PHiD-CV and may  not be sufﬁcient to
each the new equilibrium [53–55]. Indeed, experience with the 7-
alent PCV (PrevenarTM/PrevnarTM, Pﬁzer) indicated that herd effect
s not always apparent in all age groups at the same time [55]. The
otential signs of replacement by NVT serotypes should be assessed
arefully. In addition, further studies should be done to evaluate the
ffect of PHiD-CV introduction on diseases such as AOM, sinusitis,
onjunctivitis, or exacerbations of chronic obstructive pulmonary
isease that might be prevented by the NTHi protein D contained
n PHiD-CV [56].
Finally, the two other PCVs have been available in Brazil dur-
ng the study period and, in theory, may  have contributed to the
bserved effect of PHiD-CV. However, the 7- and 13-valent PCVs
ere available only through the private health system to a small
roportion of the population (<8% of children in 2007) [57,58]. Thus,
hese vaccines should not have affected the results in the different
tudies presented here.
. Conclusions
Pneumococcal disease represents an important health and
conomic burden in Brazil. Our review shows that PHiD-CV intro-
uction in the national immunization program for young children
ad a positive impact on IPD, pneumonia, AOM, and carriage,
ith emerging data on beneﬁts for unvaccinated age groups for
PD and pneumonia. These ﬁndings extend the results of RCTs to
etter understand the public health value of this vaccine after it
as introduced in a national immunization program. However,
ctive surveillance of pneumococcal infections, notably due to NVT
neumococci, and comprehensive coverage data is needed to con-
inue evaluating the overall epidemiological impact of PHiD-CV in
razil.
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